Citations

Clear

4847 citation(s) found for "Tu, Eric".

A practical guide to the implementation of AI in orthopaedic research, Part 6: How to evaluate the performance of AI research?
Oettl, Felix C. , Pareek, Ayoosh , Winkler, Philipp W. , Zsidai, Bálint , Pruneski, James A. , Senorski, Eric Hamrin , Kopf, Sebastian , Herbst, Elmar , Oeding, Jacob F. , Hirschmann, Michael T. , Musahl, Volker , Samuelsson, Kristian , Tischer, Thomas , Group, ESSKA Artificial Intelligence Working, Oettl, Felix C. , Herbst, Elmar , Oeding, Jacob F , Hirschmann, Michael T , Musahl, Volker , Samuelsson, Kristian , Feldt, Robert , Hamrin Senorski, Eric , Ley, Christophe , Grassi, Alberto , Feldt, Robert , Group, ESSKA Artificial Intelligence Working

Mayo Clinic

Journal of Experimental Orthopaedics | May 31, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/jeo2.12039 | PMID 38826500 Get It

AbstractArtificial intelligence's (AI) accelerating progress demands rigorous evaluation standards to ensure safe, effective integration into healthcare's high‐stakes decisions. As AI increasingly enables prediction, analysis and judgement capabilities relevant to medicine, proper evaluation and interpretation are indispensable. Erroneous AI could endanger patients; thus, developing, validating and deploying medical AI demands adhering to strict, transparent standards centred on safety, ethics and responsible oversight. Core considerations include assessing performance on diverse real‐world data, collaborating with domain experts, confirming model reliability and limitations, and advancing interpretability. Thoughtful selection of evaluation metrics suited to the clinical context along with testing on diverse data sets representing different populations improves generalisability. Partnering software engineers, data scientists and medical practitioners ground assessment in real needs. Journals must uphold reporting standards matching AI's societal impacts. With rigorous, holistic evaluation frameworks, AI can progress towards expanding healthcare access and quality.Level of EvidenceLevel V.
Are orthopaedic randomized controlled trials as statistically fragile as portrayed? A call for improved interpretation of the statistical fragility index
Oeding, Jacob F. , Samuelsson, Kristian , Samuelsson, Kristian , Oeding, Jacob F , Ayeni, Olufemi R. , Senorski, Eric Hamrin , Zaffagnini, Stefano , Grassi, Alberto

Mayo Clinic

Journal of Experimental Orthopaedics | May 31, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/jeo2.12042 | PMID 38826499 Get It

Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
Smith, Caleb J. , Grierson, Patrick , Morelli, Maria Pia , Patel, Sandip Pravin , Ulrickson, Matthew L. , Dahiya, Saurabh , Liechty, Kirstin B., Tebbets, Jessica , Welch, John S. , Go, William Y., Maloney, David G. , Ng, Eric Wai-Choi , Hecht, J. Randolph, Simeone, Diane M. , Kirtane, Kedar , Park, Jong Chul , Specht, Jennifer M. , Fakih, Marwan , Maus, Marcela V

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1604-1604

10.1200/jco.2024.42.16_suppl.1604 Get It

1604 Background: Diversity in clinical studies is essential to address health disparities, but racial and ethnic minorities are often underrepresented in clinical studies, especially in precision medicine studies using genetic data (1). BASECAMP-1 (NCT04981119) is an ongoing prescreening study to identify patients with unresectable advanced or metastatic solid tumors and tumor-associated HLA-A*02 LOH for the EVEREST-1 and -2 Tmod chimeric antigen receptor T-cell therapy trials. When enrollment began in 2021, eligibility for Part 1 was restricted to patients with germline HLA-A*02:01 based on preclinical data. Additional analysis revealed the blocker in the Tmod construct had activity across HLA-A*02 subtypes (Mock, et al. Mol Ther Oncolytics.2022). Eligibility for Part 1 was then expanded to all HLA-A*02 subtypes, allowing enrollment of more diverse patient populations. HLA-A*02 allele subtypes vary by ethnicity and race; the frequency of HLA-A*02:01 is 96% in non-Hispanic Whites, but ranges from 53% to 73% in other ethnicities and races. The frequency of all other HLA-A*02 allele subtypes (HLA-A*02:XX) is <5% in non-Hispanic Whites but up to 66% in other ethnicities and races (2,3). Methods: Patients eligible for BASECAMP-1 were identified at United States study sites. All patients screened before January 16, 2024, for Part 1 were included for demographic and central lab HLA-A typing. The % increase in eligibility and % of heterozygous HLA-A*02 patients with HLA-A*02:XX were calculated by ethnicity and race. Results: A total of 1124 patients were screened for germline HLA-A*02 typing; 431 patients were HLA-A*02:01 heterozygous, of whom 37 (9%) were Hispanic, 14 (3%) African American (AA), 2 (<1%) American Indian or Alaska Native, 17 (4%) Asian or Pacific Islander (API), and 324 (75%) non-Hispanic White (Table). The eligibility expansion identified 62 patients with HLA-A*02:XX heterozygosity, of whom 6 (10%) were Hispanic, 6 (10%) AA, 19 (31%) API, and 25 (40%) non-Hispanic White. Conclusions: By expanding enrollment to include HLA-A*02:XX, 16% more Hispanic, 43% more AA, and 112% more API patients were identified, improving the diversity in this trial compared with that of initial enrollment. 1. Aldrighetti, et al. JAMA Netw Open 2021. 2. Ellis, et al. Human Immunol. 2000. 3. Gragert, et al. Human Immunol.2013. Clinical trial information: NCT04981119 . [Table: see text]
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).
Hennessy, Maeve, Huang, Chiung Yu, Cimino‐Mathews, Ashley , Denbow, Rita , Rimawi, Mothaffar F. , Storniolo, Anna Maria , Valero, Vicente , Vaklavas, Chris, Krop, Ian E. , Thompson, E. Aubrey , Connolly, Roisín M. , Rimawi, Mothaffar , Fernández-Martínez, Aranzazu , Abramson, Vandana G. , Specht, Jennifer M. , Vaklavas, Christos , Winer, Eric P. , Wolff, Antonio C. , Wahl, Richard L. , Stearns, Vered , Perou, Charles M. , Carey, Lisa A.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 530-530

10.1200/jco.2024.42.16_suppl.530 Get It

530 Background: Robust biomarkers are needed to personalize treatment in early stage HER2-positive breast cancer. The TBCRC026 trial (n=83) demonstrated that early metabolic changes on FDG-PET/CT [>40% decline in SULmax at day 15 post treatment initiation (C1D15); C1D15 SULmax] were associated with response to neoadjuvant trastuzumab/pertuzumab (HP), without chemotherapy, in an ER-negative, HER2-positive cohort (NCT01937117). We investigated the association of RNA sequencing (RNAseq)-based gene expression signatures (GES) at baseline and on-treatment (C1D15), with early metabolic change on PET/CT and clinical outcomes. Methods: RNAseq (664 GES) was performed on baseline (n=56) and C1D15 (n=31) tumor biopsies (25 paired samples available). Association with pCR following HP (secondary), PET/CT parameters and survival (exploratory) was studied. Gene expression changes between baseline and C1D15 samples were tested by Wilcoxon signed-rank test. Association between GES and PET/CT parameters and GES with pCR were evaluated using logistic regression models. Cox regressions were performed to study the association between PET/CT SULmax at C1D15 and a B cell signature and relapse-free survival (RFS). The likelihood ratio test was used to compare the prognostic ability of two nested Cox models. Results: Both RNAseq and clinical outcomes were available in 53/83 patients. HER2-enriched (HER2-E) intrinsic subtype comprised 71% (40/56) of cases at baseline and 61% (19/31) at D15; basal subtype for 27% (15/56) and 39% (12/31), respectively. pCR rate was 19% (10/53) with all but one exhibiting HER2-E subtype. One basal-like sample underwent pCR, with downregulation of HER2 amplicon and IgG signatures slightly more prominent. Gene expression changes from baseline to C1D15 were analyzed; ERBB2was downregulated after HP (p = 0.007), B cell signatures, CD4, CD8, natural killer cells and Treg cells were significantly upregulated at C1D15. GES associated with 40% decline in SULmax at C1D15 included ERBB2 amplicon genes ( ERBB2, GRB7) and correlation to the HER2-E subtype, whereas basal-like signatures were significantly associated with lack of response on PET at C1D15. Univariate logistic regression analysis suggested that FOS-JUN, fibroblast and B cell GES at baseline were significantly associated with pCR (p=<0.05). Finally, the addition of a B cell signature improved the prognostic value of C1D15 SULmax on PET/CT for RFS (p < 0.05). Conclusions: In this unique cohort with ER-negative, HER2-positive breast cancer treated with neoadjuvant HP without chemotherapy, HER2-E tumors and those with increased immune signaling were more likely to respond to HER2-directed therapy. Combining C1D15 SULmax on PET/CT and a B cell signature provided improved prognostic information and should be further explored as candidate biomarkers in this setting. Clinical trial information: NCT01937117 .
Exaggerated Inspiratory Muscle Metaboreflex in Arterial Hypertension
Cifci, Gizem , Bruhn, Eric J., Bissen, Thomas G. , Olson, Thomas P. , Smith, Joshua R. , Smith, Joshua R

Mayo Clinic

Journal of the American Heart Association | May 28, 2024 | Volume: 13 | Issue: 11 | Pages: No page available

10.1161/jaha.123.033511 | PMID 38804227 Get It

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Zanwar, Saurabh , Le‐Rademacher, Jennifer , Durot, Éric , D’Sa, Shirley , Abeykoon, Jithma P. , Mondello, Patrizia , Kumar, Shaji , Ailawadhi, Sikandar, Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Sarosiek, Shayna , Paludo, Jonas , Parrondo, Ricardo D , Dispenzieri, Angela , Muchtar, E , Ailawadhi, Sikander , Kyle, Robert A , Delmer, Alain Jacques , Gertz, Morie A , Treon, Steven , Ansell, Stephen M , Castillo, Jorge J , Kapoor, Prashant , Le-Rademacher, Jennifer G , Mondello, Patrizia , Paludo, Jonas , Chhabra, Saurabh , Cook, Joselle , Dispenzieri, Angela , Gonsalves, Wilson I. , Muchtar, Eli , Rajkumar, S. Vincent , Delmer, Alain , Fonseca, Rafaël , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

Journal of Clinical Oncology | May 24, 2024 | Volume: 42 | Issue: 21 | Pages: 2527-2536

10.1200/jco.23.02066 | PMID 38788183 Get It

PURPOSE Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and MYD88 L265P mutation is now frequently assessed at diagnosis, warranting reexamination of the prognostic parameters. PATIENTS AND METHODS We reviewed records of 889 treatment-naïve patients with active WM, consecutively seen between January 01, 1996, and December 31, 2017, to identify clinical predictors of overall survival (OS) in univariate analyses. Patients with complete data for the parameters significant on the univariate analyses (n = 341) were included in a multivariable analysis to derive a prognostic model, subsequently validated in a multi-institutional cohort. RESULTS In the derivation cohort (n = 341), age (hazard ratio [HR], 1.9 [95% CI, 1.2 to 2.1]; P = .0009), serum lactate dehydrogenase (LDH) above upper limit of normal (HR, 2.3 [95% CI, 1.3 to 4.5]; P = .007), and serum albumin <3.5 g/dL (HR, 1.5 [95% CI, 0.99 to 2.3]; P = .056) were independently prognostic. By assigning a score of 1 point each to albumin <3.5 g/dL (HR, 1.5) and age 66-75 years (HR 1.4) and 2 points for age >75 years (HR, 2.6) or elevated LDH (HR, 2.3), four groups with distinct outcomes were observed on the basis of the composite scores. Five-year OS was 93% for the low-risk (score 0), 82% for low-intermediate risk (score 1), 69% for intermediate-risk (score 2), and 55% for the high-risk (score ≥3; P < .0001) groups. In the validation cohort (N = 335), the model maintained its prognostic value, with a 5-year OS of 93%, 90%, 75%, and 57% for the four groups, respectively ( P < .0001). CONCLUSION Modified Staging System for WM (MSS-WM), utilizing age, albumin, and LDH is a simple, clinically useful, and externally validated prognostic model that reliably risk-stratifies patients with symptomatic WM into four groups with distinct prognosis.
ICSNT Primer for the Skull Base Community: Navigating the Landscape of Sinonasal Tumors with Synthesized Literature Guidance
Adappa, Nithin D. , London, Nyall R. , Smith, Timothy L. , Su, Shirley Y. , Wang, Marilene B. , Adappa, Nithin D. , Kuan, Edward C , Holtzman, Adam L. , Wang, Marilene B , Su, Shirley Y , Wang, Eric W , Adappa, Nithin D. , Beswick, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 23, 2024 | Volume: 86 | Issue: 03 | Pages: 373-376

10.1055/s-0044-1787155 | PMID 40351885 Get It

Myopathy With Crescent of Nuclei: A Novel Histopathologic Finding in Desminopathy
Granger, Andre , Sorenson, Eric J. , Selcen, Duygu , Liewluck, Teerin

Mayo Clinic

Journal of Clinical Neuromuscular Disease | May 21, 2024 | Volume: 25 | Issue: 4 | Pages: 197-198

10.1097/cnd.0000000000000493 | PMID 38771229 Get It

Reply to Barajas-Ochoa: The Imperative to Integrate International Medical Graduates into the Infectious Diseases Physician-Scientist Pathway: Expanding Opportunities and Overcoming Barriers
Swartz, Talia H. , Apewokin, Senu , Carpenter, Stephen M. , Chakraborty, Rana , Dennis, Ann M. , Houpt, Eric R. , Surana, Neeraj K. , Zerr, Danielle M. , Pirofski, Liise-anne , Swartz, Talia H , Pirofski, Liise‐anne

Mayo Clinic

The Journal of Infectious Diseases | May 21, 2024 | Volume: 230 | Issue: 3 | Pages: 781-782

10.1093/infdis/jiae272 | PMID 38775090 Get It